Evidence map›Paper›PMID 35384831›Full record

ArticleMicrobial genomics2022

A

Kedibone M Ndlangisa, Mignon du Plessis, Stephanie Lo, Linda de Gouveia, Chrispin Chaguza, Martin Antonio, Brenda Kwambana-Adams, Jennifer Cornick, Dean B Everett, Ron Dagan and 32 more

Abstract read
In one paragraph

Article in Microbial genomics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Population snapshot ofMicrobial genomics · 2025
    Article
  5. Article
  6. Review
  7. Investigating two decades ofMicrobial genomics · 2025
    Article
  8. Genomic characterization ofMicrobial genomics · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. Geographic migration and vaccine-induced fitness changes ofbioRxiv : the preprint server for biology · 2023
    Article
  13. AMicrobial genomics · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

42 authors.

Kedibone M NdlangisaNational Institute for Communicable Diseases (NICD), a division of the National Health Laboratory Service, Johannesburg, South Africa.
Mignon du PlessisNational Institute for Communicable Diseases (NICD), a division of the National Health Laboratory Service, Johannesburg, South Africa.
Stephanie LoParasites and Microbes, Wellcome Sanger Institute, Hinxton, UK.
Linda de GouveiaNational Institute for Communicable Diseases (NICD), a division of the National Health Laboratory Service, Johannesburg, South Africa.
Chrispin ChaguzaParasites and Microbes, Wellcome Sanger Institute, Hinxton, UK.
Martin AntonioWHO Collaborating Centre for New Vaccines Surveillance, Medical Research Council Unit, The Gambia at London School of Hygiene & Tropical Medicine, Fajara, The Gambia.
Brenda Kwambana-AdamsNIHR Global Health Research Unit on Mucosal Pathogens, Division of Infection and Immunity, University College London, London, UK.
Jennifer CornickMalawi-Liverpool-Wellcome-Trust, Blantyre, Malawi.
Dean B EverettMalawi-Liverpool-Wellcome-Trust, Blantyre, Malawi.
Ron DaganThe Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Paulina A HawkinsRollins School Public Health, Emory University, Atlanta, USA.
Bernard BeallCenters for Disease Control and Prevention, Atlanta, USA.
Alejandra CorsoAdministración Nacional de Laboratorios e Institutos de Salud, Buenos Aires, Argentina.
Samanta Cristine Grassi AlmeidaCenter of Bacteriology, Adolfo Lutz Institute, São Paulo, Brazil.
Theresa J OchoaInstituto de Medicina Tropical, Universidad Peruana Cayetano Heredia, Lima, Peru.
Stephen ObaroUniversity of Nebraska Medical Center, Omaha, USA.
Sadia ShakoorThe Aga Khan University, Karachi, Pakistan.
Eric S DonkorDepartment of Medical Microbiology, University of Ghana Medical School, Accra, Ghana.
Rebecca A GladstoneParasites and Microbes, Wellcome Sanger Institute, Hinxton, UK.
Pak Leung HoDepartment of Microbiology and Carol Yu Centre for Infection, The University of Hong Kong, Queen Mary Hospital, Hong Kong, PR China.
Metka ParagiNational Laboratory of Health, Environment and Food, Ljubljana, Slovenia.
Sanjay DoiphodeHamad Medical Corporation, Doha, Qatar.
Somporn SrifuengfungFaculty of Pharmacy, Siam University, Bangkok, Thailand.
Rebecca FordPapua New Guinea Institute of Medical Research, Goroka, Papua New Guinea.
Jennifer MoïsiAgence de Médecine Préventive, Paris, France.
Samir K SahaChild Health Research Foundation, Dhaka, Bangladesh.
Godfrey BigogoKenya Medical Research Institute, Kisumu, Kenya.
Betuel SigauqueCentro de Investigação em Saúde da Manhiça, Maputo, Moçambique.
Özgen Köseoglu EserHacettepe University Faculty of Medicine, Department of Medical Microbiology, Ankara, Turkey.
Naima ElmdaghriFaculty of Medicine and Pharmacy & Ibn Rochd University Hospital Center, Casablanca, Morocco.
Leonid TitovThe Republican Research and Practical Center for Epidemiology and Microbiology, Minsk, Belarus.
Paul TurnerCentre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
K L Ravi KumarKempegowda Institute of Medical Sciences Hospital & Research Center, Bangalore, India.
Rama KandasamyUniversity of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, UK.
Ekaterina EgorovaG. N. Gabrichevsky Research Institute for Epidemiology and Microbiology, Moscow, Russia.
Margaret IpDepartment of Microbiology, Chinese University of Hong Kong, Hong Kong, PR China.
Robert F BreimanThe Emory Global Health Institute, Atlanta, USA.
Keith P KlugmanSchool of Pathology, University of the Witwatersrand, Johannesburg, South Africa.
Lesley McGeeCenters for Disease Control and Prevention, Atlanta, USA.
Stephen D BentleyParasites and Microbes, Wellcome Sanger Institute, Hinxton, UK.
Anne von GottbergNational Institute for Communicable Diseases (NICD), a division of the National Health Laboratory Service, Johannesburg, South Africa.
The Global Pneumococcal Sequencing ConsortiumThe Global Pneumococcal Sequencing Project (http://www.pneumogen.net/gps/.), UK.

Funding

PS08-868, S. Africa: EXPANSION OF HIV/AIDS, STD AND TB LABORATORY ACTIVITIES AT THE NATIONAL INSTITUTEU2GPS001328 · PS · NATIONAL HEALTH LABORATORY SERVICE · PI VAN HEERDEN, DR. JOHAN · 2008 to 2012
$44.4M
NCHHSTP CDC HHS U2G PS001328Wellcome Trust
6 · The paper itself

Abstract

Pneumococcal serotype 35B is an important non-conjugate vaccine (non-PCV) serotype. Its continued emergence, post-PCV7 in the USA, was associated with expansion of a pre-existing 35B clone (clonal complex [CC] 558) along with post-PCV13 emergence of a non-35B clone previously associated with PCV serotypes (CC156). This study describes lineages circulating among 35B isolates in South Africa before and after PCV introduction. We also compared 35B isolates belonging to a predominant 35B lineage in South Africa (GPSC5), with isolates belonging to the same lineage in other parts of the world. Serotype 35B isolates that caused invasive pneumococcal disease in South Africa in 2005-2014 were characterized by whole-genome sequencing (WGS). Multi-locus sequence types and global pneumococcal sequence clusters (GPSCs) were derived from WGS data of 63 35B isolates obtained in 2005-2014. A total of 262 isolates that belong to GPSC5 (115 isolates from South Africa and 147 from other countries) that were sequenced as part of the global pneumococcal sequencing (GPS) project were included for comparison. Serotype 35B isolates from South Africa were differentiated into seven GPSCs and GPSC5 was most common (49 %, 31/63). While 35B was the most common serotype among GPSC5/CC172 isolates in South Africa during the PCV13 period (66 %, 29/44), 23F was the most common serotype during both the pre-PCV (80 %, 37/46) and PCV7 period (32 %, 8/25). Serotype 35B represented 15 % (40/262) of GPSC5 isolates within the global GPS database and 75 % (31/40) were from South Africa. The predominance of the GPSC5 lineage within non-vaccine serotype 35B, is possibly unique to South Africa and warrants further molecular surveillance of pneumococci.

Indexed as

Pneumococcal InfectionsStreptococcus pneumoniaeHumansPneumococcal VaccinesSerogroupSouth AfricaVaccines, ConjugatePneumococcal VaccinesVaccines, Conjugateglobal pneumococcal sequence clusterserotype 35BSouth AfricaStreptococcus pneumoniae

Identifiers

PMID35384831
PMCPMC9453074

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.